0001209191-20-032794.txt : 20200528 0001209191-20-032794.hdr.sgml : 20200528 20200528202634 ACCESSION NUMBER: 0001209191-20-032794 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200516 FILED AS OF DATE: 20200528 DATE AS OF CHANGE: 20200528 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DENYES NANCY CENTRAL INDEX KEY: 0001640869 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37378 FILM NUMBER: 20923688 MAIL ADDRESS: STREET 1: C/O ATYR PHARMA, INC. STREET 2: 3545 JOHN HOPKINS COURT, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: Krueger Nancy DATE OF NAME CHANGE: 20150429 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: aTYR PHARMA INC CENTRAL INDEX KEY: 0001339970 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203435077 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-731-8389 MAIL ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-16 0 0001339970 aTYR PHARMA INC LIFE 0001640869 DENYES NANCY 3545 JOHN HOPKINS COURT, SUITE 250 SAN DIEGO CA 92121 0 1 0 0 General Counsel Common Stock 2020-05-16 4 M 0 892 A 3057 D Common Stock 2020-05-20 4 S 0 322 3.62 D 2735 D Employee Stock Option (right to buy) 4.06 2020-05-26 4 A 0 30000 0.00 A 2030-05-26 Common Stock 30000 30000 D Restricted Stock Unit 2020-05-16 4 M 0 892 0.00 D Common Stock 892 0 D Restricted stock units (RSU) convert into common stock on a one-for-one basis. Includes 178 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 15, 2020. Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on May 16, 2018. 50% of the shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 26, 2020, such that these shares will be fully exercisable on May 26, 2024; 25% of the shares subject to this option will vest on May 26, 2021 if and only if a clinical development milestone is achieved by September 30, 2020; and the remaining 25% of the shares will vest on May 26, 2021 if and only if an additional clinical development milestone is achieved by September 30, 2020. The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on May 16, 2019. Nancy E. Denyes 2020-05-28